Pharmaceutical composition comprising a gamma-cyclodextrin-based polymer

drug discovery

today’s cyclodextrin:
it makes me particularly happy to post about the recent success of Heegon Kim and RENATUS, as I have known and admired Heegon’s work for a while and we share a vision of the importance of developing CD-based therapies. Renatus develops gamma-cyclodextrin-based polymer to prevent or treat cholesterol metabolism-related diseases to minimize cell membrane cholesterol extraction, thus exhibiting an excellent anti-inflammatory effect by causing no cytotoxicity and hemolytic activity, making intracellular cholesterol metabolism and release easy and effectively inhibiting the release of IL-1β, MCP-1, and TNF-α.

See the complete patent here: PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-CYCLODEXTRIN POLYMER AND USE THEREOF


Targeting bacterial virulence as a novel treatment against AMR infections

drug development, ,

Have you known that Arivin Therapeutics uses cyclodextrin for targeting bacterial virulence as a novel treatment against AMR infections? Among their MoA claims, the following are listed:
– Targeting virulence factors is effective, also against extensively resistant isolates
– Targeting virulence avoids rapid resistance
– Direct reduction in inflammatory responses
– Potentiates the function of antibiotics
Also, there is a spectacular video about how CDs develop their effect as antibacterials.

https://arivintx.com/our-science

Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis

drug discovery,

Fascinating research from University of North Carolina at Chapel Hill, The State University of New York and Rensselaer Polytechnic Institute on using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis.

Yongmei Xu, Katelyn Arnold, Fuming Zhang, Vijayakanth Pagadala, Robert Linhardt et al.

See the full article here.